$TARO on NYSE
January 30, 2024
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
January 17, 2024
Taro Announces Merger Agreement with Sun Pharma
October 26, 2023
Taro Provides Results for September 30, 2023
October 19, 2023
Taro to Release Second Quarter Results on October 26, 2023
July 26, 2023
Taro Provides Results for the Quarter Ended June 30, 2023
July 19, 2023
Taro to Release First Quarter Results on July 26, 2023
July 19, 2023
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro
June 30, 2023
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
May 23, 2023
Taro Provides Results for Year Ended March 31, 2023
May 18, 2023
Taro to Release Full Year Results on May 23, 2023
January 24, 2023
Taro Provides Results for December 31, 2022
January 19, 2023
Taro to Release Third Quarter Results on January 24, 2023
October 27, 2022
Taro Provides Results for September 30, 2022
October 24, 2022
Taro to Release Second Quarter Results on October 27, 2022
August 11, 2022
Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements
July 27, 2022
Taro Provides Results for the Quarter Ended June 30, 2022
July 26, 2022
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
July 26, 2022
Taro to Release First Quarter Results on July 27, 2022
May 26, 2022
Taro Provides Results for the Year Ended March 31, 2022
May 20, 2022
Taro to Announce Full Year Results on May 26, 2022
February 28, 2022
Taro Completes Acquisition of Alchemee
February 22, 2022
Taro to Acquire Alchemee From Galderma
January 27, 2022
Taro Provides Results for December 31, 2021
January 20, 2022
Taro to Announce Third Quarter Results on January 27, 2022
December 01, 2021
Taro Appoints New Chief Financial Officer
October 28, 2021
Taro Provides Results for September 30, 2021
October 21, 2021
Taro to Announce Second Quarter Results on October 28, 2021
July 27, 2021
Taro Provides Results for Quarter Ended June 30, 2021
July 20, 2021
Taro to Announce First Quarter Results on July 27, 2021
July 14, 2021
Taro Announces Resignation of Chief Financial Officer
June 18, 2021
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021
May 19, 2021
Taro Provides Results for the Year Ended March 31, 2021
May 12, 2021
Taro to Announce Full Year Results on May 19, 2021
January 27, 2021
Taro Provides Results for December 31, 2020
January 20, 2021
Taro to Announce Third Quarter Results on January 27, 2021
October 28, 2020
Taro Provides Results for September 30, 2020
October 21, 2020
Taro to Announce Second Quarter Results on October 28, 2020
September 28, 2020
Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.
July 29, 2020
Taro Provides Results for Quarter Ended June 30, 2020
July 23, 2020
Taro Achieves Global Resolution of DOJ Antitrust Investigations
July 22, 2020
Taro to Announce First Quarter Results on July 29, 2020
June 19, 2020
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2020
May 19, 2020
Taro Provides Results for the Year Ended March 31, 2020
May 12, 2020
Taro to Announce Full Year Results on May 19, 2020
April 06, 2020
Taro Appoints New Chief Financial Officer
February 20, 2020
Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Phenytoin Oral Suspension USP, 125 mg/5 mL Due to Possible Underdosing or Overdosing
February 03, 2020
Taro Provides Results for December 31, 2019
January 28, 2020
Taro to Announce Third Quarter Results on February 3, 2020
January 10, 2020
Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles
December 19, 2019
Taro Announces Final Results of Its Tender Offer
- No Recent Filings Found.
